

**A. SYRINGE LABEL**

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Syringe**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ecomectin 18.7 mg/g Oral Paste for Horses  
Ivermectin

**2. STATEMENT OF ACTIVE SUBSTANCES**

Ivermectin 18.7 mg/g

**3. PHARMACEUTICAL FORM**

Oral Paste

**4. PACKAGE SIZE**

6.42 g or 7.49 g

**5. TARGET SPECIES**

Horses

**6. INDICATION(S)**

Antiparasitic treatment for Horses.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet or outer carton before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period(s):  
Meat and offal: 34 days  
Do not use in mares producing milk for human consumption

**9. SPECIAL WARNING(S), IF NECESSARY**

**10. EXPIRY DATE**

EXP MM/YYYY

The product is for single use. After use the syringe should be discarded

**11. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

ACME DRUGS s.r.l.  
Via Portella della Ginestra 9  
42025 Cavriago  
Italy

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 61301/3001

**17. MANUFACTURER'S BATCH NUMBER**

Lot

**B. BOX LABEL**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Box**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ecomectin 18.7 mg/g Oral Paste for Horses  
Ivermectin

**2. STATEMENT OF ACTIVE SUBSTANCES**

1 Syringe containing 7.49 g (6.42 g) paste which contains 18.7 mg/g ivermectin

**3. PHARMACEUTICAL FORM**

Oral Paste

**4. PACKAGE SIZE**

6.42 g or 7.49g

**5. TARGET SPECIES**

Horses

**6. INDICATION(S)**

Antiparasitic treatment for Horses.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

One syringe will treat up to a 700 kg horse (only for 7.49 g syringe)  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period(s):  
Meat and offal: 34 days  
Do not use in mares producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use for full instructions and user warnings

**10. EXPIRY DATE**

(EXP) MM/YYYY

The product is for single use. After use the syringe should be discarded.

**11. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

ACME DRUGS s.r.l.  
Via Portella della Ginestra 9  
42025 Cavriago  
Italy

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 61301/3001

**17. MANUFACTURER’S BATCH NUMBER**

Lot

## **C. PACKAGE LEAFLET**

## PACKAGE LEAFLET

Ecomectin 18.7 mg/g Oral Paste for Horses

### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

ACME DRUGS s.r.l.  
Via Portella della Ginestra 9  
42025 Cavriago  
Italy

Manufacturer for the batch release:

ACME Drugs S.r.l.  
Via Portella della Ginestra, 9, Zona Industriale Corte Tegge  
42025 CAVRIAGO (RE)  
Italy

### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ecomectin 18.7 mg/g Oral Paste for Horses  
Ivermectin

### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each g contains:

**Active substance:**

Ivermectin                      18.7 mg

**Excipients:**

Titanium dioxide (E171) 20 mg

A white homogeneous paste

#### **4. INDICATION(S)**

Treatment of nematode or arthropod infection due to:

Large strongyles:

*Strongylus vulgaris* (adults and L<sub>4</sub> stage larvae [arterial])

*Strongylus edentatus* (adults and L<sub>4</sub> stage larvae [tissue])

*Strongylus equinus* (adults)

Small strongyles (including benzimidazole resistant strains):

*Cyathostomum* spp (adults and luminal L<sub>4</sub> stage larvae)

*Cylicocyclus* spp. (adults and luminal L<sub>4</sub> stage larvae)

*Cylicodontophorus* spp. (adults and luminal L<sub>4</sub> stage larvae)

*Cylicostephanus* spp. (adults and luminal L<sub>4</sub> stage larvae)

*Gyalocephalus* spp. (adults and luminal L<sub>4</sub> stage larvae)

Ascarids:

*Parascaris equorum* (luminal L<sub>5</sub> larvae and adults)

Pinworms:

*Oxyuris equi* (L<sub>4</sub> stage larvae and adults)

Neck threadworms:

*Onchocerca* spp (microfilariae)

Stomach bots:

*Gasterophilus* spp (oral and gastric stages)

#### **5. CONTRAINDICATIONS**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs or cats as severe adverse reactions may occur.

#### **6. ADVERSE REACTIONS**

The effects of GABA agonists are increased by ivermectin

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

#### **7. TARGET SPECIES**

Horses

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

### **Dosage:**

One syringe division of paste per 100 kg body weight (based on a recommended dosage of 200 microgram ivermectin per kg body weight).. The syringe containing 6.42 g of paste delivers sufficient paste to treat 600 kg of bodyweight at the recommended dose rate.

The syringe containing 7.49 g of paste delivers sufficient paste to treat 700 kg of bodyweight at the recommended dose rate.

### **Administration:**

The paste is given by oral route.

## **9. ADVICE ON CORRECT ADMINISTRATION**

To ensure administration of a correct dose, body weight should be determined as accurately as possible. The animal's mouth should be free from food to ensure swallowing. Turn the screw gauge on the syringe plunger to the body weight of the horse. The tip of the syringe barrel should be inserted at the interdental space (the gap between the front and back teeth) and the paste deposited on the base of the tongue. Advance the plunger as far as it will go, depositing the medication on the base of the tongue. Immediately elevate the horse's head for a few seconds to ensure swallowing.

## **10. WITHDRAWAL PERIOD(S)**

Meat and offal: 34 days

Do not use in mares producing milk for human consumption.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the reach and sight of children.

Do not store above 25°C

The product is for single use. After use, the syringe should be discarded.

Do not use after expiry date which is stated on the label/carton

## **12. SPECIAL WARNING(S)**

### **Special precautions for use in animals**

Some horses with heavy infections of *Onchocerca* spp. microfilariae have experienced oedema and pruritus following treatment. Such reactions are assumed to be the result of death of large numbers of microfilariae. These signs resolve within a few days but symptomatic treatment may be advisable

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class over an extended period of time,
- Underdosing, which may be due to underestimation of body weight or misadministration of the product.

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

Veterinary advice should be given on appropriate dosing programs and stock management to achieve adequate parasite control and reduce the likelihood of anthelmintic resistance developing. In the event that a product is suspected of being ineffective, the animal owner is advised to seek veterinary advice.

Resistance to ivermectin has been reported in *Parascaris equorum*. Therefore, the use of this product should be based on local farm epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics

Since ivermectin is highly bound to plasma proteins, special care should be taken in cases of sick animals or in nutritional conditions associated with low plasma protein levels.

Dogs and cats should not be allowed to ingest spilled gel or have access to used packaging due to the potential for adverse effects related to ivermectin toxicity

The product has been formulated for use in horses only. Cats, dogs, especially Collies, Old English Sheepdogs and related breeds or crosses, and also turtles and tortoises may be adversely affected by the concentration of ivermectin in this product if they are allowed to ingest spilled paste or have access to used syringes.

The product can be administered to mares at any stages of pregnancy or lactation.

Mild transitory signs (slowed pupillary light response and depression) have been seen at a higher dose of 1.8 mg/kg (9 times the recommended dose level). Other signs seen at higher doses include mydriasis (dilation of the pupil), ataxia (incoordination), tremors (shaking), stupor (dull), coma and death. The less severe signs have been transitory.

Although no antidote has been identified, symptomatic therapy may be beneficial.

### **User warnings**

Do not smoke, eat or drink while handling the product.

Wash hands after use.

This product may cause skin and eye irritation. Therefore, the user should avoid contact of the product with the skin and the eyes. In case of contact, rinse immediately with plenty of water.

In the case of accidental ingestion or eye irritation after contact seek medical advice immediately and show the package insert or the label to the physician.

### **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY**

EXTREMELY DANGEROUS TO FISH AND AQUATIC LIFE. Do not contaminate surface waters or ditches with product or used container. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

### **14. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

### **15. OTHER INFORMATION**

For Animal Treatment Only

Pack size:

Box containing 1 syringe of 6,42 g

Box containing 1 syringe of 7,49 g

Box containing 50 syringes of 7,49 g

Not all pack sizes may be marketed

**B. BOX LABEL**  
**Box of 50 syringes**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Box of 50 syringes**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ecomectin 18.7 mg/g Oral Paste for Horses  
Ivermectin

**2. STATEMENT OF ACTIVE SUBSTANCES**

Ivermectin 18.7 mg/g  
A white homogeneous paste

**3. PHARMACEUTICAL FORM**

Oral Paste

**4. PACKAGE SIZE**

Each syringe containing 7.49 g paste which contains 18.7 mg/g ivermectin  
50 syringes per box

**5. TARGET SPECIES**

Horses

**6. INDICATION(S)**

Treatment of nematode or arthropod infection due to:

Large strongyles:

*Strongylus vulgaris* (adults and L<sub>4</sub> stage larvae [arterial])  
*Strongylus edentatus* (adults and L<sub>4</sub> stage larvae [tissue])  
*Strongylus equinus* (adults)

Small strongyles (including benzimidazole resistant strains):

*Cyathostomum* spp (adults and luminal L<sub>4</sub> stage larvae)  
*Cylicocyclus* spp. (adults and luminal L<sub>4</sub> stage larvae)  
*Cylicodontophorus* spp. (adults and luminal L<sub>4</sub> stage larvae)  
*Cylicostephanus* spp. (adults and luminal L<sub>4</sub> stage larvae)  
*Gyalocephalus* spp. (adults and luminal L<sub>4</sub> stage larvae)

Ascarids:  
*Parascaris equorum* (luminal L<sub>5</sub> larvae and adults)

Pinworms:  
*Oxyuris equi* (L<sub>4</sub> stage larvae and adults)

Neck threadworms:  
*Onchocerca* spp (microfilariae)

Stomach bots:  
*Gasterophilus* spp (oral and gastric stages)

## **7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Dosage:

One syringe division of paste per 100 kg body weight (based on a recommended dosage of 200 microgram ivermectin per kg body weight).

The syringe containing 7.49 g of paste delivers sufficient paste to treat 700 kg of bodyweight at the recommended dose rate.

Administration:

The paste is given by oral route.

To ensure administration of a correct dose, body weight should be determined as accurately as possible. The animal's mouth should be free from food to ensure swallowing. Turn the screw gauge on the syringe plunger to the body weight of the horse. The tip of the syringe barrel should be inserted at the interdental space (the gap between the front and back teeth) and the paste deposited on the base of the tongue. Advance the plunger as far as it will go, depositing the medication on the base of the tongue. Immediately elevate the horse's head for a few seconds to ensure swallowing.

## **8. WITHDRAWAL PERIOD(S)**

Withdrawal periods(s)

Meat and offal: 34 days

Do not use in mares producing milk for human consumption.

## **9. SPECIAL WARNING(S), IF NECESSARY**

### **Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs or cats as severe adverse reactions may occur.

## **Adverse reactions**

The effects of GABA agonists are increased by ivermectin

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon

## **Special precautions for use in animals**

Some horses with heavy infections of *Onchocerca* spp. microfilariae have experienced oedema and pruritus following treatment. Such reactions are assumed to be the result of death of large numbers of microfilariae. These signs resolve within a few days but symptomatic treatment may be advisable

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class over an extended period of time,
- Underdosing, which may be due to underestimation of body weight or misadministration of the product.

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

Veterinary advice should be given on appropriate dosing programs and stock management to achieve adequate parasite control and reduce the likelihood of anthelmintic resistance developing. In the event that a product is suspected of being ineffective, the animal owner is advised to seek veterinary advice.

Resistance to ivermectin has been reported in *Parascaris equorum*. Therefore, the use of this product should be based on local farm epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics

Since ivermectin is highly bound to plasma proteins, special care should be taken in cases of sick animals or in nutritional conditions associated with low plasma protein levels.

Dogs and cats should not be allowed to ingest spilled gel or have access to used packaging due to the potential for adverse effects related to ivermectin toxicity

The product has been formulated for use in horses only. Cats, dogs, especially Collies, Old English Sheepdogs and related breeds or crosses, and also turtles and tortoises may be adversely affected by the concentration of ivermectin in this product if they are allowed to ingest spilled paste or have access to used syringes.

The product can be administered to mares at any stages of pregnancy or lactation.

Mild transitory signs (slowed pupillary light response and depression) have been seen at a higher dose of 1.8 mg/kg (9 times the recommended dose level). Other signs seen at higher doses include mydriasis (dilation of the pupil), ataxia (incoordination), tremors (shaking), stupor (dull), coma and death. The less severe signs have been transitory.

Although no antidote has been identified, symptomatic therapy may be beneficial.

### **User warnings**

Do not smoke, eat or drink while handling the product.

Wash hands after use.

This product may cause skin and eye irritation. Therefore, the user should avoid contact of the product with the skin and the eyes. In case of contact, rinse immediately with plenty of water.

In the case of accidental ingestion or eye irritation after contact seek medical advice immediately and show the package insert or the label to the physician.

### **10. EXPIRY DATE**

(EXP) MM/YYYY

The product is for single use. After use the syringe should be discarded.

### **11. SPECIAL STORAGE CONDITIONS**

Do not store above 25 °C

### **12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

EXTREMELY DANGEROUS TO FISH AND AQUATIC LIFE. Do not contaminate surface waters or ditches with product or used container. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

### **13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Marketing authorisation holder

ACME DRUGS s.r.l.  
Via Portella della Ginestra 9  
42025 Cavriago  
Italy

Manufacturer for the batch release:

ACME Drugs S.r.l.  
Via Portella della Ginestra, 9, Zona Industriale Corte Tegge  
42025 CAVRIAGO (RE)  
Italy

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 61301/3001

**17. MANUFACTURER'S BATCH NUMBER**

Lot XXXX

*Gavin Hall*  
Approved: 29 August 2025